Literature DB >> 8655466

Hypoxic preconditioning in isolated rat hearts: non-involvement of activation of adenosine A1 receptor, Gi protein, and ATP-sensitive K+ channel.

K Yabe1, Y Nasa, S Takeo.   

Abstract

Activation of the adenosine A1(A1) receptor, Gi protein, and ATP-sensitive K+ (KATP)-channel system has been shown to play an important role in the cardioprotective effects of ischemic preconditioning in dogs. The present study was undertaken to elucidate the possible involvement of this system in hypoxic preconditioning, which ameliorates injury induced by prolonged ischemia and subsequent reperfusion in perfused rat hearts. Ten minutes of hypoxic preconditioning resulted in an appreciable improvement of post-ischemic cardiac contractile recovery. This was associated with a significant reduction in the release of creatine kinase (CK) from reperfused hearts. Hypoxic preconditioning shortened the time to ischemic contracture onset and prevented a further rise in left ventricular end-diastolic pressure (LVEDP) during reperfusion. Neither the selective A1 receptor antagonist, 8-cyclopentyltheophylline (CPT) nor the KATP channel blocker, glibenclamide, altered the beneficial effects of hypoxic preconditioning. In vivo pretreatment with an inhibitor of Gi protein, pertussis toxin (PTX), also did not diminish the preconditioning effect. The results suggest that, although hypoxic preperfusion ameliorates post-ischemic contractile dysfunction, neither the activation of the A1 receptor, nor the opening of the KATP-channel, nor transduction through Gi protein are involved in the post-ischemic functional recovery of hypoxic preconditioning in the perfused rat heart.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8655466     DOI: 10.1007/bf02911387

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  55 in total

1.  Adenosine antagonism by purines, pteridines and benzopteridines in human fibroblasts.

Authors:  R F Bruns
Journal:  Biochem Pharmacol       Date:  1981-02-15       Impact factor: 5.858

2.  The ATP-sensitive potassium channel blocker glibenclamide (glyburide) does not abolish preconditioning in isolated ischemic rat hearts.

Authors:  G J Grover; S Dzwonczyk; P G Sleph; C A Sargent
Journal:  J Pharmacol Exp Ther       Date:  1993-05       Impact factor: 4.030

3.  Limitation of infarct size in the rabbit by ischaemic preconditioning is reversible with glibenclamide.

Authors:  C F Toombs; T L Moore; R J Shebuski
Journal:  Cardiovasc Res       Date:  1993-04       Impact factor: 10.787

4.  Adenosine inhibits exocytotic release of endogenous noradrenaline in rat heart: a protective mechanism in early myocardial ischemia.

Authors:  G Richardt; W Waas; R Kranzhöfer; E Mayer; A Schömig
Journal:  Circ Res       Date:  1987-07       Impact factor: 17.367

5.  Acadesine lowers temporal threshold for the myocardial infarct size limiting effect of preconditioning.

Authors:  A Tsuchida; G S Liu; K Mullane; J M Downey
Journal:  Cardiovasc Res       Date:  1993-01       Impact factor: 10.787

6.  Ischemic preconditioning is associated with a delay in ischemia-induced reduction of beta-adrenergic signal transduction in rabbit hearts.

Authors:  T Iwase; T Murakami; T Tomita; S Miki; K Nagai; S Sasayama
Journal:  Circulation       Date:  1993-12       Impact factor: 29.690

7.  Glibenclamide antagonizes adenosine A1 receptor-mediated cardioprotection in stunned canine myocardium.

Authors:  Z Yao; G J Gross
Journal:  Circulation       Date:  1993-07       Impact factor: 29.690

8.  Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs.

Authors:  G J Gross; J A Auchampach
Journal:  Circ Res       Date:  1992-02       Impact factor: 17.367

9.  Ischemic preconditioning protects against infarction in rat heart.

Authors:  Y Liu; J M Downey
Journal:  Am J Physiol       Date:  1992-10

10.  Antiarrhythmic effects of preconditioning in anaesthetised dogs and rats.

Authors:  A Vegh; S Komori; L Szekeres; J R Parratt
Journal:  Cardiovasc Res       Date:  1992-05       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.